reports
Beyond Cancer Abstract Featuring Phase 1 Data on Intratumoral Ultra-Hi...
Beyond Cancer Abstract Featuring Phase 1 Data on Intratumoral Ultra-High Concentration Nitric Oxide (UNO) in Solid Tumor Metastases to be Presented at the AACR Annual Meeting 2026 GARDEN CITY, N.Y., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., a clinical stage biotechnology company developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors and subsidiary of Beyond Air, Inc. (NASDAQ: XAIR), today announced being selected to present an abstract featuring data from the Phase 1 trial of intratumoral UNO in solid tumor metastases at the American A...
Beyond Air to Participate in Two Upcoming Healthcare Investor Conferen...
Beyond Air to Participate in Two Upcoming Healthcare Investor Conferences GARDEN CITY, N.Y., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide to improve the lives of patients, today announced that Steve Lisi, Chairman & Chief Executive Officer of Beyond Air, will participate in the 13th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference being held February 9th to 11th in Snowbird, UT and the Noble Cap...
Beyond Air Schedules Third Fiscal Quarter 2026 Financial Results Confe...
Beyond Air Schedules Third Fiscal Quarter 2026 Financial Results Conference Call and Webcast GARDEN CITY, N.Y., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that it will report financial results for its third fiscal quarter ended December 31, 2025 on Friday, February 13, 2026. The Company's management team is scheduled to host a conference call and webcast at 8:00 am East...
Beyond Air Announces $5.0 Million Private Placement Priced At-the-Mark...
Beyond Air Announces $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules GARDEN CITY, N.Y., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide to improve the lives of patients, today announced that it entered into a securities purchase agreement with an institutional investor to issue and sell, in a private placement priced at-the-market under Nasdaq rules, 3,930,818 shares of common stock (or pre-funded warrants...
XTL Biopharmaceuticals Acquires 85% of Beyond Air’s Subsidiary NeuroNO...
XTL Biopharmaceuticals Acquires 85% of Beyond Air’s Subsidiary NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership Unmatched scientific firepower: Two Nobel Laureates join Founder Prof. Haitham Amal, leading global autism researcher Critical unmet need: 1 in 31 U.S. children now affected, zero FDA-approved disease-modifying therapies exist FDA Orphan Drug designations secured for autism-related Phelan-McDermid Syndrome (PMS) and Glioblastoma Platform targets the core biology of autism, not just symptomatic relief Beyond Air (NASDAQ: XAIR), majorit...
Beyond Air® Appoints Dan Moorhead as Chief Financial Officer
Beyond Air® Appoints Dan Moorhead as Chief Financial Officer GARDEN CITY, N.Y., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced the appointment of Dan Moorhead as Chief Financial Officer, effective January 5, 2026. Duke Dewrell, the Company's Controller, who had assumed CFO responsibilities at the Company on an interim basis in November 2025, will resume his prior role as of...
Beyond Air® Signs New International LungFit PH® Distribution Agreement...
Beyond Air® Signs New International LungFit PH® Distribution Agreements, Most Notably in Germany and Brazil Distribution network coverage expanded to a total of 39 countries GARDEN CITY, N.Y., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced the recent signing of several key international distribution agreements for LungFit® PH, expanding its network to include Germany, Bra...
Sensient Technologies Corp: 1 director
A director at Sensient Technologies Corp sold 4,518 shares at 94.809USD and the significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...
Beyond Air® Announces Transition of Chief Financial Officer
Beyond Air® Announces Transition of Chief Financial Officer Launched search for permanent successor GARDEN CITY, N.Y., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that Doug Larson has resigned as Chief Financial Officer to pursue another opportunity. Mr. Larson will continue to serve as CFO through December 5, 2025, at which time the CFO responsibilities at the Company...
- Jonathan Moreland
PPSI PIONEER POWER SOLUTIONS
PEB PEBBLEBROOK HOTEL TRUST
PCTY PAYLOCITY HOLDING CORP.
OPK OPKO HEALTH INC.
LOB LIVE OAK BANCSHARES
GOGO GOGO INC.
GLP GLOBAL PARTNERS LP
FLDM FLUIDIGM
FAST FASTENAL COMPANY
CPSI COMPUTER PROGRAMS & SYSTEMS INC.
CNS COHEN & STEERS INC.
MSM MSC INDUSTRIAL DIRECT CO. INC. CLASS A
INTT INTEST CORP.
MIRM MIRUM PHARMACEUTICALS
TSLX SIXTH STREET SPECIALTY LENDING
MYPS INC.
QDEL PLAYSTUDIOS INC
GTE QUIDEL CORP
ET GRAN TIERRA ENERGY INC.
MXF ENERGY TRANSFER LP
GDV THE MEXICO FUND
INC.
THE GABELLI DIVIDEND & INCOME TRUST
- Jonathan Moreland
RGP RESOURCES CONNECTION INC.
FTAI FORTRESS TRANSPORTATION AND INFRASTRUCTURE INVESTORS LLC
FAST FASTENAL COMPANY
TZOO TRAVELZOO
ITGR INTEGER HOLDINGS CORPORATION
BX THE BLACKSTONE GROUP L.P.
REZI RESIDEO TECHNOLOGIES
AEYE INC.
BW AUDIOEYE INC
PNTG BABCOCK & WILCOX ENTERPRISES
MRVI PENNANT GROUP
UPST MARAVAI LIFESCIENCES HOLDINGS
NEXT UPSTART HOLDINGS
CLVT NEXT CAPITAL
OGN CLARIVATE PLC
MYPS ORGANON & CO
FRST PLAYSTUDIOS INC
RBA PRIMIS FINANCIAL CORP
CRVO RITCHIE BROS AUCTIONEERS INC.
GAM CERVOMED INC
MDRR GENERAL DE ALQUILER DE MAQUINARIA
SENS MEDALIST DIVERSIFIED REIT INC.
BATRK SENSEONICS HOLDINGS INC.
LIBERTY MEDIA CORP
Beyond Air® Reports Fiscal Second Quarter 2026 Financial Results and P...
Beyond Air® Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update Increased revenue by 128% year over year (YoY) to $1.8 million Appointed Beyond Air Board member Bob Goodman as Interim Chief Commercial Officer Raised $12.0 million in debt financing; proforma cash, cash equivalents, restricted cash and marketable securities of $22.9 million as of September 30, 2025 Achieves certificate for Medical Device Single Audit Program (MDSAP) Updated fiscal year 2026 revenue guidance to $8 – $10 million Conference call at 4:30 p.m. ET today, November 10th GARDEN CI...
Beyond Air® Secures Up to $32 Million to Accelerate Growth
Beyond Air® Secures Up to $32 Million to Accelerate Growth Enters agreements for a $12 million promissory note and a $20 million equity line of credit with Streeterville Capital Proforma cash, cash equivalents, restricted cash and marketable securities of $22.9 million as of September 30, 2025, including $12 million from the promissory note Extends cash runway into calendar 2027 GARDEN CITY, N.Y., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the p...
- Jonathan Moreland
VIRC VIRCO MANUFACTURING CORP.
THFF FIRST FINANCIAL CORP. (INDIANA)
SSNC SS&C TECHNOLOGIES HOLDINGS INC.
PNFP PINNACLE FINANCIAL PARTNERS INC.
FDS FACTSET RESEARCH SYSTEMS INC.
DENN DENNY'S CORPORATION
CNS COHEN & STEERS INC.
CMC COMMERCIAL METALS COMPANY
CAPL CROSSAMERICA PARTNERS LP
CAG CONAGRA BRANDS INC.
ANGO ANGIODYNAMICS INC.
ASA ASA
ADC AGREE REALTY CORPORATION
ATRO ASTRONICS CORPORATION
RVP RETRACTABLE TECHNOLOGIES INC.
TRT TRIO TECH INTERNATIONAL
FSFG FIRST SAVINGS FINANCIAL GROUP INC.
KYN KAYNE ANDERSON MLP INVESTMENT CO.
FBK FB FINANCIAL CORPORATION
GRF EAGLE CAPITAL GROWTH FUND INC
GWRS GLOBAL WATER RESOURCES
RMCF ROCKY MOUNTAIN CHOCOLATE FACTORY INC.
BRT BRT APARTMENTS
ZIVO ZIVO BIOSCIENCE
CPSH INC.
STRO CPS TECHNOLOGIES
GRX SUTRO BIOPHARMA
PNTG THE GABELLI HEALTHCARE & WELLNESSRX TRUST
PCB PENNANT GROUP
WWR PACIFIC CITY FINANCIAL CORP
ACET WESTWATER RESOURCES
CGEM ADICET BIO INC
SMMT CULLINAN ONCOLOGY INC
INTA SUMMIT THERAPEUTICS INC
IMRX INTAPP INC
REFI IMMUNEERING CORP
VANI CHICAGO ATLANTIC REAL ESTATE FINANCE INC
EP VIVANI MEDICAL INC
SOC EMPIRE PETROLEUM CORP
LAW SABLE OFFSHORE CORP
HYMC CS DISCO INC
NUGN HYCROFT MINING HOLDING CORPORATION
LIVENTO GROUP
INC.
Beyond Air Schedules Second Fiscal Quarter 2026 Financial Results Conf...
Beyond Air Schedules Second Fiscal Quarter 2026 Financial Results Conference Call and Webcast GARDEN CITY, N.Y., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that it will report financial results for its second fiscal quarter ended September 30, 2025 on Monday, November 10, 2025. The Company's management team is scheduled to host a conference call and webcast at 4:30 pm E...
- Jonathan Moreland
VIRC VIRCO MANUFACTURING CORP.
THFF FIRST FINANCIAL CORP. (INDIANA)
SSNC SS&C TECHNOLOGIES HOLDINGS INC.
SPWH SPORTMANS WAREHOUSE HOLDINGS
PSEC PROSPECT CAPITAL CORPORATION
FDS FACTSET RESEARCH SYSTEMS INC.
CAPL CROSSAMERICA PARTNERS LP
CALM CAL-MAINE FOODS INC.
CAG CONAGRA BRANDS INC.
ANGO ANGIODYNAMICS INC.
ASA ASA
ADC AGREE REALTY CORPORATION
RIGN TRANSOCEAN LTD.
RVP RETRACTABLE TECHNOLOGIES INC.
TRT TRIO TECH INTERNATIONAL
FSFG FIRST SAVINGS FINANCIAL GROUP INC.
KYN KAYNE ANDERSON MLP INVESTMENT CO.
AMBC AMBAC FINANCIAL GROUP INC.
GWRS GLOBAL WATER RESOURCES
BRT BRT APARTMENTS
ZIVO ZIVO BIOSCIENCE
CPSH INC.
FUND CPS TECHNOLOGIES
FGBI ROYCE FOCUS TRUST
STRO INC.
SAVA FIRST GUARANTY BANCSHARES
DX SUTRO BIOPHARMA
PNTG CASSAVA SCIENCES
PCB DYNEX CAPITAL INC.
WWR PENNANT GROUP
ACET PACIFIC CITY FINANCIAL CORP
ALTM WESTWATER RESOURCES
CGEM ADICET BIO INC
OPEN ALTUS MIDSTREAM COMPANY (A)
GGZ CULLINAN ONCOLOGY INC
IMRX OPENDOOR TECHNOLOGIES INC.
REFI GABELLI GLOBAL SMALL AND MID CAP VALUE TRUST
PEPG IMMUNEERING CORP
VANI CHICAGO ATLANTIC REAL ESTATE FINANCE INC
UAMY PEPGEN INC
SOC VIVANI MEDICAL INC
LAW U S ANTIMONY CORP
MRAI SABLE OFFSHORE CORP
HYMC CS DISCO INC
SABS MARPAI
INC.
HYCROFT MINING HOLDING CORPORATION
BIG CYPRESS ACQUISITION CORP.
- Jonathan Moreland
NeuroNOS Granted FDA Orphan Drug Designation for Glioblastoma, the Mos...
NeuroNOS Granted FDA Orphan Drug Designation for Glioblastoma, the Most Common and Deadliest Primary Malignant Brain Cancer in Adults BOSTON, Sept. 08, 2025 (GLOBE NEWSWIRE) -- NeuroNOS, a biopharmaceutical company focused on developing treatments for neurological disorders and neuro-oncology, and a subsidiary of Beyond Air (NASDAQ: XAIR), today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its lead investigational therapy, BA-101, for the treatment of Glioblastoma (GBM). GBM is an aggressive primary brain tumor with limited tre...
Beyond Air to Participate in the H.C. Wainwright 27th Annual Global In...
Beyond Air to Participate in the H.C. Wainwright 27th Annual Global Investment Conference GARDEN CITY, N.Y., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that Steve Lisi, Chairman and Chief Executive Officer of Beyond Air, will participate in the H.C. Wainwright 27th Annual Global Investment Conference being held September 8-10, 2025 in New York, NY. An on-demand webc...
Beyond Air Signs New International LungFit PH® Distribution Agreements...
Beyond Air Signs New International LungFit PH® Distribution Agreements, Most Notably in Japan These recent LungFit PH international agreements bring the ex-U.S. total to 34 countries and a combined population of 2.7 billion people GARDEN CITY, N.Y., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patient lives, today announced the expansion of its global LungFit® PH distribution network. The Company has recentl...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.